

Ann Lloyd CBE, Cadeirydd | Chair

☎ 01633 435 957

✉ Ann.Lloyd@wales.nhs.uk

Nicola Prygodzicz, Prif Weithredwr | Chief Executive

☎ 01633 435 958 🐦 CEOabuhb

✉ Nicola.Prygodzicz@wales.nhs.uk



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Aneurin Bevan
University Health Board

Our ref: **FOI 23-589**

Tuesday, 30 January 2024

Thank you for your request to Aneurin Bevan University Health Board for information under the Freedom of Information Act (2000) received on 9 November 2023.

Your request

You requested the following:

I have a freedom of information request regarding the treatment of certain types of cancer. Could you please answer the following questions.

Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

- CAPOX (Capecitabine with Oxaliplatin)
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
- Lonsurf (Trifluridine - tipiracil)
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Any other systemic anti-cancer therapy
- Palliative care only

Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:

- Nivolumab monotherapy or combination with Ipilimumab
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
- Any other systemic anti-cancer therapy
- Palliative care only

Q3. How many patients were treated in the past 3 months for advanced/metastatic resected oesophageal cancer ONLY with:

Bwrdd Iechyd Prifysgol Aneurin Bevan

Pencadlys, Ysbyty Sant Cadog

Ffordd Y Llodj, Caerllion, Casnewydd NP18 3XQ

☎ 01633 436 700 📘 BwrddIechydPrifysgol 🐦 BIPANeurinBevan

Dyfodol Clinigol
Clinical Futures

Aneurin Bevan University Health Board

Headquarters, St Cadoc's Hospital
Lodge Road, Caerleon, Newport NP18 3XQ

☎ 01633 436 700 📘 AneurinBevanHealthBoard 🐦 AneurinBevanUHB

Rydym yn croesawu gohebiaeth yn Gymraeg a byddwn yn ymateb yn Gymraeg heb oedi.

Bwrdd Iechyd Prifysgol Aneurin Bevan yw enw gweithredol Bwrdd Iechyd Lleol Prifysgol Aneurin Bevan.

We welcome correspondence in Welsh and we will respond in Welsh without delay.

Aneurin Bevan University Health Board is the operational name of Aneurin Bevan University Local Health Board.

- Nivolumab monotherapy or combination with Ipilimumab
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
- Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
- Any other systemic anti-cancer therapy
- Palliative care only

Our Response

I can confirm that the Health Board has completed a search of its records and has established that it does not hold information in relation to your request below:

The Upper Gastrointestinal (UGI) cancer chemotherapy treatment is a commissioned service provided by Velindre NHS Trust (VNHST) for patients served by Aneurin Bevan University Health Board, and this request would need to be redirected to them.

Please see below the email address for submitting Freedom of Information request to VNHST.

FOI.VUNHST@wales.nhs.uk